N/A
Completed N=989
A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)
Prostatic Hyperplasia
Source: ClinicalTrials.gov NCT01003886 ↗
Enrolled (actual)
989
Serious AEs
0.0%
Results posted
Oct 2011
Primary outcomePrimary: Number of Participants With Adverse Events (AEs) — 14 Participants
Summary
This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events (AEs) |
14 | — |
| SECONDARY Percent Change From Baseline in the International Prostate Symptom (IPSS) Total Score at Week 4 and Week 12 |
22.30; -44.90; -65.10; -61.40 | — |
| SECONDARY Percent Change From Baseline in the IPSS Quality of Life (QoL) Score at Week 4 and Week 12 |
4.20; -44.60; -64.10; -60.50 | — |
| SECONDARY Change From Baseline in Systolic BP at Week 4 and Week 12 |
-3.80; -5.70 | — |
| SECONDARY Change From Baseline in Diastolic BP at Week 4 and Week 12 |
-1.50; -2.40 | — |
| SECONDARY Percentage of Participants With Postural Hypotension |
0.3 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects that will be included must be consistent with the approved label indication of Doxazosin mesylate GITS in the Philippines, which includes adult male diagnosed with BPH, and who are prescribed with Doxazosin mesylate GITS.
Exclusion Criteria
- Subjects with condition that are contraindicated with Doxazosin mesylate GITS based on the approved labeling in the Philippines.
Data sourced from ClinicalTrials.gov (NCT01003886). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.